Safe harbor for forward-looking statements and Use of Document

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “may,” “intend,” “goal,” “target,” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; our financial performance; our business plans and product performance; acquisitions; clinical trials; new and anticipated product approvals and launches; and our environmental, social and governance (ESG) plans and goals, including our environmental targets. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this presentation. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences can be found in our most recent Annual Report on Form 10-K and Quarterly Reports on Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Use of document: This document contains certain highlights with respect to our 2023 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the fourth quarter ended December 31, 2023 located in the investor section of our website at www.bostonscientific.com and our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission.

Amounts reported in millions in this presentation are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Market share information are Boston Scientific internal estimates.
Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

Our Mission + Values

- Caring
- Meaningful Innovation
- High Performance
- Global Collaboration
- Diversity
- Winning Spirit
Strategic Imperatives Guide Our Growth

Develop, Inspire and Retain Our Talent

Values: Caring, Meaningful Innovation, High Performance, Global Collaboration, Diversity, Winning Spirit
Focusing on Category Leadership

NEUROMODULATION
Electronic implantable technologies and minimally invasive therapies that help patients manage debilitating chronic pain and neurological conditions

PERIPHERAL INTERVENTIONS
Leading devices for minimally invasive treatments of peripheral vascular disease, vessel trauma and cancer

ENDOSCOPY
Minimally invasive devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions

UROLOGY
Comprehensive solutions to support kidney stone removal, prostate health, erectile restoration and urinary continence

CARDIAC RHYTHM MANAGEMENT
Groundbreaking technologies that monitor, support diagnosis, and treat irregular heart rhythms, heart failure and sudden cardiac arrest

ELECTROPHYSIOLOGY
A broad range of technologies for diagnosing and treating heart rhythm disorders

WATCHMAN
The most studied and implanted left atrial appendage closure device in the world, designed to reduce stroke risk in patients with non-valvular atrial fibrillation

INTERVENTIONAL CARDIOLOGY THERAPIES
Minimally invasive technologies to improve the lives of patients living with heart and vascular conditions
Transforming Lives Across the Globe

- 37 million patients treated each year
- 48,000 employees worldwide
- 140 countries with commercial representation

1. All figures are for the year ended December 31, 2023
Committed to Meaningful Innovation

COLLABORATIONS

RESEARCH & DEVELOPMENT

BUSINESS DEVELOPMENT

COMMUNITY OF INNOVATION